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Abstract 
Background: Understanding the key characteristics of malaria testing and treatment is essential to the control of 
a disease that continues to pose a major risk of morbidity and mortality in mainland Tanzania, with evidence of a 
resurgence of the disease in recent years. The introduction of artemisinin combination therapy (ACT) as the first-line 
treatment for malaria, alongside policies to promote rational case management following testing, highlights the need 
for evidence of anti-malarial and testing markets in the country. The results of the most recent mainland Tanzania 
ACTwatch outlet survey are presented here, including data on the availability, market share and price of anti-malarials 
and malaria diagnosis in 2016.
Methods: A nationally-representative malaria outlet survey was conducted between 18th May and 2nd July, 2016. 
A census of public and private outlets with potential to distribute malaria testing and/or treatment was conducted 
among a representative sample of administrative units. An audit was completed for all anti-malarials, malaria rapid 
(RDT) diagnostic tests and microscopy.
Results: A total of 5867 outlets were included in the nationally representative survey, across both public and private 
sectors. In the public sector, availability of malaria testing was 92.3% and quality-assured (QA) ACT was 89.1% among all 
screened outlets. Sulfadoxine–pyrimethamine (SP) was stocked by 51.8% of the public sector and injectable artesunate 
was found in 71.4% of all screened public health facilities. Among anti-malarial private-sector stockists, availability of test-
ing was 15.7, and 65.1% had QA ACT available. The public sector accounted for 83.4% of the total market share for malaria 
diagnostics. The private sector accounted for 63.9% of the total anti-malarial market, and anti-malarials were most com-
monly distributed through accredited drug dispensing outlets (ADDOs) (39.0%), duka la dawa baridi (DLDBs) (13.3%) and 
pharmacies (6.7%). QA ACT comprised 33.1% of the national market share (12.2% public sector and 20.9% private sector). 
SP accounted for 53.3% of the total market for anti-malarials across both private and public sectors (31.3 and 22.0% of the 
total market, respectively). The median price per adult equivalent treatment dose (AETD) of QA ACT in the private sector 
was $1.40, almost 1.5 times more expensive than the median price per AETD of SP ($1.05). In the private sector, 79.3% of 
providers perceived ACT to be the most effective treatment for uncomplicated malaria for adults and 88.4% perceived this 
for children.
Conclusions: While public sector preparedness for appropriate malaria testing and case management is showing 
encouraging signs, QA ACT availability and market share in the private sector continues to be sub-optimal for most out-
let types. Furthermore, it is concerning that SP continues to predominate in the anti-malarial market. The reasons for this 
remain unclear, but are likely to be in part related to price, availability and provider knowledge or preferences. Continued 
efforts to implement government policy around malaria diagnosis and case management should be encouraged.
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Background
Following declines in malaria prevalence in the first dec-
ade of the twenty first century, more recent data from 
mainland Tanzania have shown evidence of a resur-
gence in the disease. Among children under five, malaria 
prevalence halved from 18 to 9% between 2007–2008 
and 2011–2012, but has since risen to 14%. There is also 
regional variation, with prevalence as high as 28% in the 
Western zone [1]. Ninety-three percent of mainland Tan-
zania’s population resides in malaria-endemic areas, and 
in 2015 there were estimated to be 7.3 million clinical and 
confirmed cases of malaria reported in the country [2].
Tanzania Mainland’s Strategic Plan for Malaria 2015–
2020, includes goals to (1) reduce malaria illness and 
deaths by 80.0% from 2012 levels; (2) reduce malaria 
prevalence to 1.0%; and, (3) increase the proportion of 
pregnant women receiving two or more doses of sulf-
adoxine–pyrimethamine (SP) during pregnancy to 80.0% 
[3]. Malaria case management priorities are: to improve 
the quality of diagnostic and case management services; 
to maintain and improve anti-malarial drug supplies in 
the public sector; to improve access to quality and afford-
able artemisinin combination therapy (ACT) in the pri-
vate sector. The strategy further outlines specific areas of 
focus that will support these targets, including strength-
ening the supply chain, information provision and behav-
iour change communications (BCC) to promote universal 
diagnostic coverage and uptake of ACT.
The 2014 Tanzania Mainland’s National Guidelines 
for the Diagnosis and Treatment of Malaria stipulate 
artemether–lumefantrine (AL) as the first-line treat-
ment for uncomplicated malaria in both adults and chil-
dren, with dihydroartimisinin-piperaquine (DHA PPQ) 
as a second-line treatment in cases of treatment failure 
[4]. The guidelines were also updated to align with the 
World Health Organization (WHO) recommendations 
stipulating injectable (IV/IM) artesunate for treatment 
of patients with severe malaria, and a three-course treat-
ment of SP for intermittent treatment as prevention 
during pregnancy (IPTp) (rather than a two-course treat-
ment as previously recommended). According to the 
2014 National Guidelines, patients with severe malaria 
should be referred to a public health facility. Quinine is 
the second-line treatment for cases of uncomplicated 
malaria contra-indicated for ACT and for women in the 
first trimester of pregnancy, or in cases of severe malaria 
not responding to first-line treatment. The 2014 National 
Guidelines also advocate parasitological confirmation of 
suspected malaria cases for all ages in mainland Tanza-
nia. Since 2006, oral artemisinin monotherapy has been 
banned [5].
Mainland Tanzania has implemented several strategies 
in recent years to improve access to confirmatory testing 
and first-line ACT treatment. For example, between 2007 
and 2013, the mainland Tanzanian public sector received 
93.1 million doses of AL [3]. Between 2009 and 2012, a 
phased roll-out of malaria rapid diagnostic tests (RDTs) 
to all levels of government health facilities was imple-
mented to complement microscopy services, with 
national coverage in 2013 [6]. This was in line with grow-
ing recognition that relatively inexpensive and sensitive 
RDTs could be made available at the most peripheral lev-
els of the public health sector.
In 2010, mainland Tanzania participated in the 
Affordable Medicines Facility-malaria (AMFm) pilot, 
administrated by the Global Fund, with the aim of 
increasing access to ACT and reducing use of arte-
misinin monotherapy in the public and private sec-
tor [7]. ACT that achieved accredited status from the 
WHO, European Medicines Authority (EMA) or the 
Global Fund (termed quality assured [QA] ACT) were 
subsidized at ‘factory gate’ before entering the supply 
chains in countries involved in the project. AMFm-
subsidized products carried a ‘green leaf ’ logo to dif-
ferentiate them from non-subsidized and non-QA 
ACT products [8]. Following the AMFm pilot period 
in 2010–2011, the subsidy mechanism transitioned 
into a new model called the private sector co-payment 
mechanism (CPM) which continued to fund ACT sub-
sidies in the private sectors of many malaria-endemic 
countries, including mainland Tanzania [8, 9]. The 
CPM focused exclusively on the private sector sup-
ply of QA ACT given that an independent evaluation 
showed that the AMFm had greater impact on the sup-
ply of QA ACT in the private than the public sector 
[10]. The public sector continued to receive subsidized 
ACT through an alternative Global Fund mechanism, 
and QA ACT medicines in this sector were not marked 
with the ‘green leaf ’ logo.
In the 12  month period prior to data collection 
reported here, 7.3 million treatment doses were deliv-
ered in mainland  Tanzania during the CPM period, 
representing a decline from the AMFm peak—where 
21.6 million doses were delivered in 2012 (personal com-
munication, Global Fund). The CPM period was further 
marked by a reduction in the level of subsidy to first-line 
ACT buyers—from over 90% during the AMFm period to 
70%~ in 2016. During the CPM period in mainland Tan-
zania, there was an absence of any provider or consumer 
behaviour change communication or other supporting 
interventions to increase awareness of the subsidized, 
QA ACT (personal communication, Global Fund).
Several other initiatives have focused on improving 
malaria case management services in the private sec-
tor. Following the loosening of laws in mainland Tanza-
nia in 1991 that had previously banned the provision of 
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medical services in the private sector, there was a pro-
liferation and diversification of private providers [11]. A 
large proportion of outlets were registered (but essen-
tially unregulated) private medicine dispensing outlets, 
including small drug shops called duka la dawa baridi 
(DLDBs) (sometimes referred to as Part II drug outlets) 
[12]. According to the national policy, DLDBs are only 
permitted to sell non-prescription medications [13]. 
However, in practice they frequently dispensed prescrip-
tion-only treatments. In 2003, the mainland Tanzanian 
government introduced the accredited drug dispens-
ing outlet (ADDO) programme, which aimed to provide 
accreditation to these outlets, through a programme of 
training and support to increase their capacity to provide 
quality primary health services, particularly in remote 
areas [14]. As part of the accreditation process, ADDO 
providers received training on malaria case management 
and malaria national treatment guidelines [13]. ADDOs 
are permitted to sell prescription medicines, including 
ACT, while referring any cases of severe malaria to a pub-
lic health facility. Since a successful 2012 pilot initiative 
introducing testing with RDTs in ADDOs, efforts have 
been made to begin a national roll-out of RDTs in these 
outlets. There are over 4000 ADDOs located mainly in 
rural areas [15], and thought to be another 2000 outlets 
awaiting accreditation by the government nationally.
Understanding the anti-malarial and malaria diagnostic 
supply side will be an important means to inform future 
case management strategies and guide programmes 
aimed at improving adherence to national guidelines. 
Since 2010, ACTwatch has been implementing outlet 
surveys in mainland Tanzania to generate timely, relevant 
and high quality evidence about anti-malarial markets for 
policy makers, donors and implementing organizations 
[16]. In 2016, ACTwatch implemented its final survey in 
mainland Tanzania. The objective of this paper is to pro-
vide practical evidence to inform strategies and policies 
in mainland Tanzania towards achieving national malaria 
control goals. The paper describes the total market for 
malaria medicines and diagnostics at national level.
Methods
Design and sampling
The 2016 mainland Tanzania outlet survey was a nation-
ally representative, cross-sectional, quantitative sur-
vey conducted among a sample of outlets stocking 
anti-malarial medicines and diagnostics. The survey was 
implemented between 18 May and 2 July, 2016. This was 
the fourth such survey conducted in mainland Tanzania.
Detailed ACTwatch project and methodological infor-
mation have been published elsewhere [16, 17]. Briefly, 
all potential outlet types stocking anti-malarials and 
diagnostics in mainland Tanzania in both public and 
private sectors were included in the study. According to 
the ACTwatch methodology, outlets are included in the 
survey if they have the ‘potential’ to sell or distribute 
anti-malarials or diagnostic testing. This includes outlets 
that may not typically be expected to stock anti-malarial 
medicines, such as general retailers, village shops, or 
itinerant drug vendors. However, it is recognized that in 
many countries these outlets can operate as vendors for 
anti-malarial commodities, either illegally or/and outside 
of the formal health system. These outlets are included in 
the sample as a means to confirm their role or presence 
in a given country’s anti-malarial and diagnostic market. 
These outlets may differ on a country-by-country basis, 
but broad categories are used to define public and private 
sector outlets.
Outlets sampled in the public sector included pub-
lic health facilities (e.g., the national referral hospital, 
regional hospitals, district hospitals, health centres, dis-
pensaries), and private not-for-profit facilities [including 
non-governmental organizations (NGOs) hospitals and 
clinics, faith-based hospitals, clinics]. The private-sector 
outlet types sampled were private for-profit health facili-
ties (including private hospitals, clinics, diagnostic labo-
ratories), pharmacies (which are registered and licensed 
by a national regulatory authority, and staffed by phar-
macists and qualified health practitioners), ADDOs (drug 
stores that primarily sell medicines, registered with a 
national regulatory authority, where staff have received 
training), DLDBs (drug stores that primarily sell medi-
cines, with no formal licensing, and no guarantee of staff 
training), general retailers (grocery stores and village 
shops), and itinerant drug vendors (mobile, unregistered 
providers selling medicines).
The primary sampling approach taken for ACTwatch 
outlet surveys entails sampling a set of administrative 
units (geographic clusters) with a population of approxi-
mately 10,000 to 15,000 inhabitants. Clusters are selected 
with cluster probability of selection proportionate to size 
(PPS). The most appropriate administrative unit in main-
land Tanzania matching the desired population size was 
at the ward level.
Clusters (wards) were selected using probability pro-
portional to population size sampling, using data from 
the 2012 Tanzania Population and Housing Census [18]. 
Additional wards were selected for oversampling of pub-
lic health facilities, private for-profit health facilities, 
pharmacies, and ADDOs. This booster sampling strategy 
was used to obtain a sufficient sample size for indica-
tor estimates within these outlet types. The sample was 
stratified by urban–rural ward designation. In total, 58 
wards were selected for the main census sample (28 rural, 
30 urban) and a further 172 wards were selected for the 
booster sample (84 rural, 88 urban).
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Within each selected cluster a census of all outlet types 
with the potential to provide anti-malarials or diagnostics 
to consumers was undertaken. The inclusion criteria for 
outlets were: (1) one or more anti-malarials in stock on 
the day of the survey; (2) one or more anti-malarials in 
stock in the three months preceding the survey; and, (3) 
malaria blood testing (RDTs or microscopy) available.
Sample size
The study was powered to detect a minimum of a 20% 
point change in availability of QA ACT among anti-
malarial stockists between each round and within each 
domain for each survey, at the 5% significance level with 
80% power. The number of study clusters was calculated 
for each research domain based on the required num-
ber of anti-malarial stockists and assumptions about the 
number of anti-malarial stockists per cluster. Sample size 
requirements for the 2016 survey were calculated using 
information from the 2014 survey round including anti-
malarial and QA ACT availability, outlet density per clus-
ter, and design effect.
Training and fieldwork
Fieldworker training consisted of standardized classroom 
presentations and exercises as well as a field exercise. 
Examinations administered during training were used 
to select field workers, supervisors and quality control-
lers. Additional training was provided for supervisors 
and quality controllers focused on field monitoring, veri-
fication visits and census procedures. Fieldwork teams 
were provided with a list of selected clusters and official 
maps that illustrated administrative boundaries. In each 
selected cluster, fieldworkers conducted a full enumera-
tion of all the aforementioned outlet types. This included 
enumeration of outlets with a physical location, as well 
as identification of itinerant drug vendors using local 
informants. To identify outlets, fieldworkers systemati-
cally walked through each cluster, looking for the outlets. 
To distinguish between pharmacies, ADDOs and DLDBs, 
fieldworkers were trained to look for licenses hanging up 
on the wall and to prompt providers for any clarification, 
especially when these licenses were not legible. In main-
land Tanzania, pharmacies have licenses clearly displayed 
above counters, and ADDOs have a specific license that 
include a logo to recognise the outlet as part of the pro-
gramme. The primary provider/owner of each outlet was 
invited to participate in the study and the screening ques-
tions were administered to assess anti-malarial and diag-
nostic availability.
Interviews were conducted in Swahili using question-
naires that were translated from English to Swahili and 
back to English to confirm translations. A structured 
questionnaire programmed into mobile phones using 
DroidDB software was used to complete an audit of all 
anti-malarials and RDTs as well as a provider interview. 
Quality control measures implemented during the field-
work included questionnaire review by supervisors. Up 
to 20% of all outlets were also checked by quality control-
lers to verify the interview had been completed.
Protection of human subjects
The 2016 outlet survey protocol received ethical approval 
from the national ethical approval board in main-
land Tanzania (Reference number: NIMR/HQ/R.8a/
Vol. IX/2209). Provider interviews and product audits 
were completed only after administration of a standard 
informed consent form and provider consent to par-
ticipate in the study. Providers had the option to end the 
interview at any point during the study. Standard meas-
ures were employed to maintain provider confidentiality 
and anonymity.
Measures
The outlet survey questionnaire included an audit of all 
available anti-malarial medicines and RDTs. Provid-
ers were asked to show the interviewer all anti-malarial 
medicines and RDTs currently available. A product audit 
sheet captured information for each unique product in 
the outlet, including formulation, brand name, active 
ingredients and strengths, package size, manufacturer 
and country of manufacture for anti-malarials, and brand 
name, manufacturer, country of manufacture, antigens 
and parasite species for RDTs. Providers were asked to 
report the retail and wholesale price for each product as 
well as the amount distributed to individual consumers in 
the last week.
Data analysis and indicators
Data were analysed using Stata (StataCorp College Sta-
tion, TX, USA). Standard indicators were constructed 
according to definitions applied across the ACTwatch 
project, descriptions of which have been provided in 
detail elsewhere [9, 11]. Anti-malarials identified dur-
ing the outlet drug audit were classified according to 
information on drug formulation, active ingredients and 
strengths as non-artemisinin therapy, artemisinin mono-
therapy and ACT. Non-artemisinin therapy was classi-
fied as SP or other non-artemisinin therapy. Although no 
longer indicated for malaria case management, SP is still 
recommended for IPTp. Artemisinin monotherapy was 
further classified as oral and non-oral, the latter including 
medicines recommended for first-line treatment of severe 
malaria. ACT was classified as QA ACT or non-quality-
assured ACT. QA ACT were ACT granted World Health 
Organization (WHO) prequalification, ACT in compli-
ance with the Global Fund Quality Assurance Policy, on 
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the Global Fund list of approved pharmaceutical products 
for procurement, or ACT granted regulatory approval by 
the European Medicines Agency (EMA). Classification 
was completed by matching product audit information 
(formulation, active ingredients, strengths, manufacturer, 
country of manufacture, package size) to lists of approved 
medicines from the WHO, EMA and Global Fund.
QA ACT availability in the public sector was among 
all outlets screened, while in the private sector it was 
restricted to those outlets that had anti-malarials in 
stock. Anti-malarial market share, or the relative dis-
tribution of the anti-malarials to individual consumers 
recorded in the drug audit, was standardized to allow 
for meaningful comparisons between anti-malarials 
with different treatment courses and different formula-
tions. The adult equivalent treatment dose (AETD) was 
defined as the amount of active ingredient required to 
treat an adult weighing 60  kg according to WHO treat-
ment guidelines [19]. Provider reports on the amount of 
the drug sold or distributed during the week preceding 
the survey were used to calculate volumes according to 
type of anti-malarial. The volume of each drug was cal-
culated as the number of AETDs that were reported to 
have been sold/distributed during the week preceding 
the survey. Measures of volume included all dosage forms 
to provide a complete assessment of anti-malarial market 
share. Diagnostic market share was calculated from the 
number of malaria blood tests (i.e., microscopy and RDT) 
performed or distributed by outlet type as a proportion 
of all tests performed or distributed in the previous week.
Median private sector price for one AETD was calcu-
lated for QA ACT and for the most popular non-arte-
misinin therapy, which in mainland Tanzania was SP 
given it was the most common non-artemisinin therapy 
distributed. The interquartile range (IQR) is displayed 
as a measure of dispersion. Price data presented were 
collected in local currencies and converted to US dol-
lar prices (average exchange rate for the data collection 
period). Price measures included tablet anti-malarials 
only, given differences in unit costs for tablet and non-
tablet formulations. While all QA ACT are by definition 
tablet formulations, SP may be available in other formu-
lations including syrups and injections. These other for-
mulations were excluded from median price calculations.
Provider knowledge was measured as the percentage 
of providers who identified ACT as the most effective 
treatment for uncomplicated malaria. This was measured 
separately for adults and children, and is reported here by 
outlet type; 95% confidence intervals provide an indicator 
of the precision of the estimates.
Sampling weights were calculated as the inverse of the 
probability of cluster selection. All point estimates were 
weighted using survey settings and all standard errors 
calculated taking account of the clustered and stratified 
sampling strategy with the relevant suite of survey com-
mands in Stata. A finite population correction was also 
applied to adjust standard errors, as a relatively large pro-
portion of available clusters were selected for inclusion in 
the sample.
Results
Sample description
A total of 5868 outlets were screened for availability of 
anti-malarials and/or malaria blood testing services and 
2,317 were subsequently interviewed. A total of 2194 out-
lets surveyed were found to have anti-malarials in stock 
on the day of the survey, 39 had anti-malarials reportedly 
in stock during the previous 3 months but not on the day 
of the visit, and 84 had malaria blood testing available but 
no antimalarials in stock (A more detailed breakdown 
of outlet sample eligibility, by rural/urban strata may be 
found in Additional file 1).
Availability
Table  1 shows the availability of anti-malarials and 
malaria diagnosis among all screened public sector out-
lets. Across the public sector, 96.2% had any anti-malarial 
on the day of the survey. QA ACT availability was 92.0% 
among public health facilities and 65.8% among private 
not-for-profit facilities. When disaggregated by pack size 
(Additional file  2), availability of paediatric QA AL was 
62.2% in public health facilities and 23.2% in private not-
for-profit facilities. The availability of non-QA ACT was 
13.3% in public health facilities and 29.8% in private not-
for profit outlets. SP accounted for the majority of avail-
able non-artemisinin therapy, stocked by 51.8% of the 
public sector. Injectable artesunate was found in 71.4% 
of public health facilities and 24.9% private not-for-profit 
facilities.
Malaria diagnostics were available in 91.8% of pub-
lic health facilities (18.9% had microscopy and 89.3% 
stocked RDTs) and in 97.1% of private not for-profit facil-
ities (68.9% had microscopy and 89.3% had RDTs).
Across the public sector, availability of both QA ACT 
and testing was 83.5%, and this was higher in public 
health facilities (86.0%) than private not-for-profit facili-
ties (62.9%).
In the private sector, among all screened outlets, 
availability of any anti-malarial was highest among 
pharmacies (99.2%; N = 61), ADDO (96.9%; N = 1503) 
and DLDB (94.7%, N = 148). Of the 3541 general retail-
ers screened, only 0.5% had anti-malarials in stock 
(Additional file  3).Table  2 shows private sector avail-
ability of different types of anti-malarials among outlets 
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with any anti-malarial in stock on the day of the survey. 
Among anti-malarial stockists, 65.1% of the private sec-
tor had QA ACT available. In terms of availability of 
different pack sizes, 52.7% had adult pack sizes of QA 
AL in stock and 20.4% had paediatric QA AL (Addi-
tional file  4). Non-QA ACT was found in 42.9% of all 
anti-malarial stocking private outlets. ACT was most 
commonly available in anti-malarial stocking pharma-
cies (QA ACT 90.0%; non-QA ACT 98.7%). SP was the 
most commonly available non-artemisinin therapy anti-
malarial in the  therapy stocking private sector, and over 
90% of pharmacies and ADDOs had SP in stock. Oral 
quinine was also stocked by 64.6% of private sector out-
lets. Injectable artesunate was available in 34.4% of pri-
vate for-profit health facilities and 17.9% of pharmacies, 
but was otherwise largely absent from the private sector 
(Table 2).
Malaria diagnosis was available among 15.7% of the 
anti-malarial stocking private sector, and highest among 
private for-profit facilities (96.0%), followed by pharma-
cies (21.9%), ADDOs (10.2%) and DLDBs (8.1%). Avail-
ability of malarial microscopy was 5.4%; availability of 
RDTs was 14.3% in the private sector.
Price
The median price per AETD of QA ACT in the private 
sector was $1.40, and almost 1.5 times more expensive 
than the median price per AETD of SP ($1.05) (Table 3). 
The median price per AETD of non-QA ACT was $4.65. 
When disaggregated by outlet type, the price of these 
three anti-malarials was usually lower in DLDBs than 
other private outlet types (Additional file 5).
The median prices for malaria microscopy in the private 
sector was $0.70 for an adult and $0.47 for children. The 
median malaria RDT price for an adult and child was $0.93.
Anti‑malarial market share
The public sector accounted for 36.1% of all anti-malarial 
volumes distributed in the week prior to the survey. Of 
all anti-malarials distributed, 12.2% were QA ACT in the 
public sector, with public sector SP accounting for a fur-
ther 22.0% (Fig. 1).
The private sector accounted for 63.9% of the total anti-
malarial market, and anti-malarials were most commonly 
distributed through ADDOs (39.0%), DLDBs (13.3%) 
and pharmacies (6.7%). Of all the anti-malarials distrib-
uted, 29.7% were ACT in the private sector (QA ACT-
with the logo, 13.5%; 7.4 QA ACT without the logo and 
8.8% non-QA ACT). Most of the private sector ACT was 
distributed through ADDOs (17.7%). SP was the most 
commonly distributed anti-malarial in the private sector 
(31.3%). Oral AMT was absent from the market in this 
survey round.
The relative anti-malarial market share within outlet 
type is shown in Additional file 6. Of note is the similarity 
in anti-malarial mix between ADDOs and DLDBs, with 
ACT making up 45.4 and 41.8% of their distributed anti-
malarials, respectively.
Diagnostic market share
The public sector accounted for 83.4% of the total market 
share for malaria diagnostics (Fig. 2). Most of the diagnos-
tic tests distributed across the public and private sector 
were RDTs (90.2% of the total diagnostic market share).
Table 1 Availability of anti-malarials and malaria testing among all screened public sector outlets
Public health  
facility % CI
Private not for‑profit  
facility % CI
Public sector 
total % CI
N = 341 N = 65 N = 406
Any anti-malarial 96.2 (89.0, 98.8) 96.4 (79.5, 99.5) 96.2 (90.0, 98.6)
QA ACT 92.0 (84.0, 96.2) 65.8 (49.0, 79.4) 89.1 (82.5, 93.5)
non-QA ACT 13.3 (7.5, 22.5) 29.8 (17.1, 46.7) 15.1 (9.3, 23.6)
SP 51.5 (40.3, 62.6) 54.1 (36.9, 70.4) 51.8 (41.5, 61.9)
Oral Quinine 4.6 (1.8, 11.3) 51.4 (33.9, 68.6) 9.7 (6.3, 14.6)
Other non-artemisinin therapy (amodiaquine and 
parenteral quinine)
9.7 (6.5, 14.2) 9.3 (3.7, 21.4) 9.7 (6.7, 13.9)
Artesunate injection 71.4 (62.9, 78.5) 24.9 (16.0, 36.6) 66.3 (57.8, 73.8)
Any malaria testing 91.8 (85.6, 95.4) 97.1 (80.6, 99.6) 92.3 (86.7, 95.7)
Malaria microscopy 18.9 (13.3, 26.2) 68.9 (54.1, 80.6) 24.3 (18.2, 31.8)
RDTs 89.3 (82.2, 93.7) 89.3 (77.4, 95.3) 89.3 (82.9, 93.4)
QA ACT and any malaria testing 86.0 (77.9, 91.5) 62.9 (46.4, 76.8) 83.5 (76.4, 88.8)
QA ACT no malaria testing 5.9 (2.8, 12.1) 2.9 (0.4, 19.4) 5.6 (2.7, 11.2)
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Provider perceptions
Figure 3 shows the percentage of providers who reported 
that ACT was the most effective treatment for uncom-
plicated malaria for adults and children. Providers in 
the public sector perceived ACT as the most effective 
treatment for uncomplicated malaria for adults and chil-
dren (97.9 and 95.7%, respectively). In the private sector, 
79.3% of providers perceived ACT to be the most effec-
tive treatment for uncomplicated malaria for adults and 
88.4% perceived this for children. Almost one in five 
Table 2 Availability of anti-malarials and malaria testing among anti-malarial stocking private sector outlets
Private for‑profit facility 
% CI
Pharmacy % CI ADDO % CI DLDB % CI Private sector 
total % CI
N=118 N=60 N=1468 N=142 N=1800
QA ACT 73.6 (63.0, 82.0) 90.0 (75.0, 96.4) 66.3 (57.7, 74.0) 58.8 (42.8, 73.1) 65.1 (57.2, 72.3)
Non-QA ACT 66.5 (49.0, 80.4) 98.7 (94.2, 99.7) 43.3 (33.1, 54.1) 34.9 (21.3, 51.4) 42.9 (31.5, 55.1)
SP 76.8 (70.0, 82.4) 94.4 (90.2, 96.9) 92.2 (87.9, 95.0) 75.2 (62.2, 84.9) 86.3 (80.4, 90.6)
Oral quinine 63.9 (49.0, 76.6) 74.8 (61.7, 84.5) 65.2 (57.7, 72.1) 67.8 (51.5, 80.6) 64.6 (57.9, 70.8)
Other non-artemisinin 
therapy
8.1 (3.9, 16.2) 0.7 (0.1, 3.4) 2.6 (1.3, 5.3) 6.1 (2.6, 14.0) 4.0 (2.3, 7.0)
IV/IM artesunate 34.4 (26.9, 42.9) 17.9 (5.6, 44.5) 0.2 (0.1, 0.8) 0.0 (–) 2.4 (1.4, 4.0)
N=120 N=61 N=1490 N=146 N=1832
Any test 96.0 (91.1, 98.3) 21.9 (12.8, 34.8) 10.2 (6.4, 15.9) 8.1 (3.9, 16.2) 15.7 (12.6, 19.4)
Microscopy 73.9 (51.0, 88.5) 8.8 (1.8, 34.3) 0.6 (0.2, 2.3) 0.0 (–) 5.4 (2.8, 10.3)
RDT 78.5 (69.4, 85.4) 21.9 (12.8, 34.8) 9.7 (6.0, 15.3) 8.1 (3.9, 16.2) 14.3 (11.4, 17.7)
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providers working in ADDOs and DLDBs perceived that 
ACT was not the most effective treatment for adults 
(21.1 and 22.9%, respectively).
Discussion
This paper has provided a comprehensive overview of 
the malaria testing and treatment landscape in main-
land Tanzania in 2016, in both public and private sectors. 
While the public sector shows strong readiness to adhere 
to national guidelines, there is sub-optimal QA ACT 
availability and market share in the private sector. There 
is also persistent widespread distribution of SP, which 
continues to predominate the anti-malarial market.
Public sector readiness for malaria case management
The results indicate that in terms of availability, the pub-
lic sector’s level of readiness for appropriate malaria case 
management is high. The National Malaria Strategic Plan 
[3] aims for the provision of universal access to malaria 
testing and first-line treatment, and these results indicate 
that universal access has almost been achieved in this 
sector. Almost every screened outlet in the public sec-
tor had QA ACT available and over 90% of public sector 
outlets had either malaria microscopy or RDTs available, 
reflecting several strategies implemented nationally since 
2013 to scale up confirmatory testing in this sector. Only 
a small fraction (5.6%) of outlets had QA ACT avail-
able without testing, and this signifies an improvement 
since 2014 (where 9.5% of public sector outlets had QA 
ACT but no testing) [20]. Furthermore, three-quarters 
of public health facilities had injectable artesunate, the 
first-line treatment for severe malaria, and this reflects 
a substantial increase in the public sector since the pre-
vious survey round, from 21.3% in 2014 [20] to 66.3% in 
2016. National efforts to align with the WHO recommen-
dations for treatment of severe malaria are reflected in 
these findings. The results for provider knowledge in the 
public sector were also encouraging, and stand in con-
trast to a previous study that found overall poor levels of 
knowledge of AL in this sector [21].
Despite these promising findings, there are some gaps 
in public sector readiness for malaria case management 
that require attention. Of concern is the finding that SP 
was available in just over half of all screened outlets in 
the public sector, meaning that much of the public sector 
is not equipped to provide IPTp, although this reflects an 
increase from 2011 and 2014 [22]. This is also in light of 
several national strategies that have encouraged universal 
coverage of IPTp during pregnancy and substantial roll-
out of IPTp3+  nationwide. The findings from the most 
recent outlet survey suggest there are key challenges to 
Table 3 Median private sector price (and IQRs) for  anti-
malarials and malaria blood testing
N Median price (USD) IQR
QA ACT 2251 $1.40 [1.24–1.86]
Non-QA ACT 1381 $4.65 [1.5–6.25]
SP 4239 $1.05 [0.93–1.40]
Microscopy (adult) 88 $0.70 [0.47–0.93]
Microscopy (child) 88 $0.47 [0.47–0.93]
RDT (adult) 247 $0.93 [0.47–0.93]
RDT (child) 247 $0.93 [0.47–0.93]
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be addressed, including maintaining a constant supply of 
SP across the public health sector. This will be important 
to address in order to meet national targets that stipulate 
80% coverage of IPTp by 2020.
In addition, despite widespread availability of QA ACT 
and sub-optimal availability of SP, the market share find-
ings illustrate that SP was more widely administered 
than QA ACT in the public sector. QA ACT market 
share within the public sector was also at its lowest level 
since before the launch of the AMFm, only one in three 
anti-malarials distributed in the public sector were a QA 
ACT in 2016 compared to one in every two in 2010 [22]. 
These findings may reflect stock-outs of different pack 
sizes of QA ACT. While the strength of all first-line AL 
tablets for treatment of uncomplicated malaria is indeed 
the same, the implementation of the AL policy includes 
delivery of four different AL pack sizes (6, 12, 18 and 24 
tablets) suitable for management of four different weight 
categories of patients (5–14; 15–24; 25–34; ≥35  kg). In 
the public sector, availability of the different weight cat-
egories was variable. For example, a pack size of 12 tab-
lets of QA AL was available in less than half of the public 
sector outlets. Providers may ration ACTs because of 
uncertainty with supply coupled with availability of 
non-recommended treatments [23]. Alternatively, this 
may reflect an increase of RDTs in this sector and better 
management of patients through confirmatory testing, 
lending to a reduction of QA ACT market share. Other 
population based evidence from mainland Tanzania 
between 2010 and 2012 reported a significant decrease in 
the percentage of people with fever obtaining ACT from 
57.4 to 46.1%, along with an increase in the percentage of 
people obtaining a blood test from 28.7 to 46.6% [24]. As 
such, the market share findings from this outlet survey 
may reflect increases in diagnostic coverage and better 
management of patients.
The role of the private sector in malaria case management
In 2016, almost all pharmacies, ADDOs and DLDBs that 
were screened were in the business of stocking malaria 
commodities, as were around three-quarters of private 
not for-profit facilities. Consistent with previous out-
let surveys [20], general retailers are not typically anti-
malarial stockists. Of the 3540 screened outlets, only ten 
had anti-malarials in stock in 2016. Market share data 
also illustrate the importance of the private sector, which 
accounted for 63.9% of the total anti-malarial market. 
Anti-malarials in the private sector were also most com-
monly distributed through ADDOs.
The concentration of malaria commodities distributed 
among ADDOs may reflect several strategies to license 
DLDBs. Since 2003, the ADDO programme has been 
implemented as a means to regulate and improve service 
provision of health care in the private sector. The findings 
from 2016 illustrate that ADDOs accounted for over 1468 
anti-malarials stockists in the private sector compared to 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Adult Child Adult Child Adult Child Adult Child Adult Child Adult Child Adult Child Adult Child Adult Child
Public
Health
Facility
Private
not for-Profit
Facility
Public
Sector
Total
Private
for-Profit
Facility
Pharmacy ADDO DLDB General
Retailer
Private
Sector
Total
Pe
rc
en
t o
f p
ro
vi
de
rs
ACT most effecve
SP most effecve
Don't Know
Other most effecve
Fig. 3 Provider perceptions of the most effective treatment for uncomplicated malaria
Page 11 of 15ACTwatch Group  et al. Malar J  (2017) 16:202 
142 DLDBs, representing the greatest concentration of 
private sector service delivery points for malaria. This 
reflects a change in market composition from previous 
surveys, where in 2010 most of the private sector anti-
malarial service delivery points were DLDBs (48% of 
the total market composition) as compared to ADDOs 
(20% of the market composition) [22]. These findings are 
reflective of the several initiatives by the mainland Tan-
zania government over the years to scale up the ADDO 
programme and increase coverage of regulated pri-
vate sector outlets. As of 2015, between 4000 and 9000 
DLDBs had been accredited, becoming ADDOs, nation-
ally in mainland Tanzania [15].
Readiness and performance of the private sector 
for malaria case management
Where anti-malarials were available in the private sector, 
just over half of the anti-malarial stockists had QA ACT 
available. Market share data also illustrated that in 2016 
around 30% of the private sector market share comprised 
ACT, reflecting an overall increase from 2010 [22]. Non-
artemisinin therapy, typically SP, accounted for one-half 
of all anti-malarials distributed. The availability of malaria 
confirmatory testing was also very low in the private sec-
tor. This is corroborated by household survey data that 
found only 2.1% of febrile children under five received 
a confirmatory test in the private sector [24]. However, 
where confirmatory testing was available, the results also 
demonstrate that the median price of all malaria diagnos-
tics was lower than QA ACT, which is encouraging as it 
may provide a cost incentive for a patient to test before 
treatment.
While ADDOs accounted for the largest distribution 
of QA ACT, and comprised most of the market share 
in the private sector, there was very little difference in 
the anti-malarial mix across outlet types, given SP was 
the most commonly dispensed anti-malarial across all 
outlets. Lessons on how to maintain and improve ACT 
availability and distribution among these outlet types 
can be learnt from several studies that have investigated 
factors which influence ADDO ACT stocking charac-
teristics. Studies have found that ADDOs with greater 
client load and which are in close proximity to other 
outlets that sell ACT medicines, are more likely to stock 
ACT as compared to isolated outlets which serve fewer 
customers [25, 26]. Another determinant of ACT stock-
ing practices among ADDOs has been the presence of 
a licensed pharmacist [25, 26], and somewhat related 
to this, staff retention. One study found that up to 40% 
of trained ADDO dispensers were no longer working at 
the outlet, and consequently other untrained staff were 
employed lending to poor dispensing practices, irra-
tional use of medicines, and even poorer performance 
than DLDBs [27]. Future strategies to improve the 
retention rate of trained personnel at ADDOs will be 
key to ensure the sustainability of an effective ADDO 
programme and may want to consider the targeting 
of busier outlets in competitive markets to encourage 
faster uptake of ACT.
In addition to their role in the provision of anti-malar-
ial medication, ADDOs are now permitted to perform 
testing (using RDTs) for malaria. Nevertheless, there 
is little to differentiate ADDOs from their unregulated 
counterparts in terms of malarial blood testing avail-
ability, with RDT stocking levels languishing below 10%. 
Indeed, this mirrors challenges documented in other 
countries, where maintaining constant supply of RDTs 
have been noted, as well as determining effective incen-
tives for private providers and patients to use RDTs and 
adhere to results [28]. Despite these challenges, sev-
eral studies have documented the feasibility of includ-
ing RDT testing in ADDOs. For example, a randomized 
controlled trial to investigate whether the introduction 
of RDTs among ADDOs improved malaria case manage-
ment found that confirmatory diagnosis increased from 
19 to 74% in intervention districts, which also resulted 
in improved targeting of ACT to patients with malaria 
[29]. Similar positive outcomes have been demonstrated 
in other countries, [30, 31], with studies concluding 
that private sector outlets can safely and correctly test 
for malaria with appropriate training, supervision, and 
record keeping [32]. Scaling up access to RDTs in the 
private sector through ADDOs will be an important 
initiative to improve levels of confirmatory testing and 
treatment practices. Of promise is that the mainland 
Tanzania National Strategic Plan includes strategies to 
improve accessibility and affordability of RDTs by facili-
tating the procurement of quality diagnostic devices at 
subsidized/low costs through the global partnership [3]. 
The findings from the 2016 study provide a benchmark 
from which this can be measured.
Given evidence from this survey that ADDOs are the 
most important private sector outlet in the provision of 
anti-malarials, future strategies can target these outlets 
as a means to disrupt the widespread distribution of SP 
for case management, increase uptake of ACT and RDTs. 
Future training and learning opportunities provide an 
opportunity to emphasize the importance of adhering to 
national treatment guidelines, address misconceptions 
that SP is the most effective treatment for adults, and 
ensure constant supply of QA ACT and RDTs to these 
providers. In short, there is significant opportunity with 
regard to the role that ADDOs play in the rationalization 
of malaria treatment and diagnosis, particularly given 
their predominance in the anti-malarial private sector 
market and current efforts to engage with this sector.
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Market performance of the green leaf ACT logo
The results from the most recent survey illustrate that 
the market share of ACT remained less than 50% and 
ACT carrying the ‘green leaf ’ logo (a marker of subsi-
dized QA ACT) was less than 15%. This also reflected 
a decline from 2014 levels, which was the result of an 
upward trend in market share since the introduction 
of the subsidy mechanism [10]. These findings are per-
haps not surprising considering the transition from a 
dedicated donor funding during the AMFm period to a 
country specific grant funding mechanism, which was 
further amplified by a reduction in funding for co-paid 
ACT. Indeed, the number of subsidized QA ACT doses 
delivered to mainland Tanzania’s private sector through 
the CPM was a third of what it was in 2012. Further-
more, the ACT price subsidy in 2016 was 70% com-
pared to ~90% during the AMFm period, lending to an 
increase in QA ACT price over the years [22] such that 
the price of QA ACT was one and a half times that of SP 
in 2016. In this context, the reduction in the green leaf 
logo market share to the relatively low levels reported 
in this paper may largely be explained by a more limited 
supply and availability of these medications in the con-
text of reduced funding and scaled down programming. 
Furthermore, in the absence of supportive interventions, 
including behaviour change communications designed 
to increase awareness of the QA ACT with the logo, pro-
viders and consumers alike may have less awareness of 
the first-line, subsidized treatment. Indeed, the results 
from this study illustrated that in the private sector ACT 
is still not universally perceived as the most effect treat-
ment for uncomplicated malaria. Up to one in five pro-
viders continued to cite treatments that were not ACTs. 
In absence of supportive interventions targeted at both 
consumers and providers to raise awareness of afford-
able, quality, first-line treatment for malaria, behaviour 
change will be challenging [33].
Availability and distribution of non‑QA ACT
In the private sector, availability and distribution of non-
QA ACT was common. One in every three ACT medi-
cines distributed were non-QA ACT, and distribution 
was most common among private for-profit facilities 
and pharmacies as compared to other private sector out-
let types. This is of concern given that quality-assurance 
status has been associated with high quality medicines in 
drug quality studies [34]. In Tanzania, a nationally repre-
sentative survey of over 1700 anti-malarials in the private 
sector found that ACT samples lacking WHO prequali-
fication were 25 times more likely to be of poor qual-
ity than those with WHO prequalification status [35], 
illustrating how quality-assurance status can serve as an 
important indicator of ACT drug quality.
While public sector outlets may be required to obtain 
particular drugs that meet certain quality standards, 
quality may not necessarily be a factor in private sector 
procurement decisions. This may in part explain why the 
private sector was found to stock and distribute non-QA 
ACT. What is of interest however is that non-QA ACT 
was three times more expensive that QA ACT, yet it was 
still being distributed, indicating that some consumers 
were willing to pay over four USD for a treatment. This 
raises the question of why consumers would pay more 
for non-QA ACT when less expensive QA ACT are avail-
able. Non-QA ACT products were primarily available 
and distributed by private for-profit facilities and phar-
macies, which are more common anti-malarial service 
delivery points in urban areas as compared to rural areas 
in Tanzania [22]. As outlets located in urban areas typi-
cally serve consumers with a higher socio-economic sta-
tus [22, 36], these consumers may be able to better afford 
the relatively high price of non-QAACT. Or, this could 
be related to a lack of awareness of subsidy programme, 
given demand creation strategies had not been promoted 
in the past several years. Indeed, a better understanding 
of provider and consumer demand for QA ACT and non-
QAACT will be important for developing strategies to 
promote use of QA ACT over non-QA products.
Availability and use of SP
The results from the 2015 illustrate the widespread avail-
ability and distribution of SP, and this is a barrier to 
implementation of the government policy for first-line 
treatments for uncomplicated malaria. Furthermore, 
while SP is mandated for use in IPTp, it seems likely 
from these results that it is also being utilized more 
widely than government policy recommends. Govern-
ment efforts to encourage universal coverage of IPTp 
during pregnancy may have driven increased demand 
for SP, and there is some evidence that levels of IPTp 
have increased in recent years [1]. However, while there 
has been a substantial roll-out of IPTp3+  nationwide, 
with parallel behaviour change communication and pro-
motion through public health facilities, there is no evi-
dence or policy documents suggesting that the private 
sector should also play a role in the provision of this ser-
vice in the country. Continued uses of SP likely include 
management of fever/malaria in people of all ages given 
the widespread availability and distribution of this 
anti-malarial.
The substantial private sector SP market share is 
cause for concern, and suggests it is being adminis-
tered for malaria case management, against national 
(and international) guidelines. This is also supported 
by other evidence that suggests many SP products have 
packaging and patient instructions indicating its use 
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for uncomplicated malaria for all ages. Additional file  7 
shows some example photographs of SP packaging col-
lected during fieldwork, some of which clearly indi-
cate that the product is appropriate for the treatment of 
malaria for all ages. Other research in mainland Tanzania 
has corroborated these findings and illustrated that SP 
was predominantly distributed to men [37].
Limitations
The results presented in this study provided a cross-sec-
tional snapshot of the anti-malarial testing and treatment 
markets in mainland Tanzania in 2016. The ACTwatch 
outlet survey design has limitations that have been doc-
umented and reported elsewhere [17, 38]. Limitations 
specific to the mainland Tanzania study centre around 
potential bias emerging from interviews with DLDBs, 
for whom the practice of supplying prescription medica-
tions is not permitted. All vendors participating in this 
study gave their informed consent to take part, and were 
assured of their anonymity. It is feasible that vendors 
may deflate or increase the levels of anti-malarial testing 
or treatment that they are reporting. The use of an elec-
tronic data collection approach, while convenient from 
a data collection perspective, may have had the effect 
of arousing suspicion among the interviewees. In addi-
tion, the study was not designed or powered to compare 
ADDOs and DLDBs, but it did provide an opportunity 
to examine these outlet types and explore their perfor-
mance. In addition, it is uncertain that these two outlet 
types were substantively different, as DLDBs may have 
begun, but not yet completed the accreditation process at 
the time of the survey, or indeed may have competed the 
process previously and then lost their accreditation.
Conclusion
Tanzania is in a unique position in that several strate-
gies have been in place to improve malaria case manage-
ment services and this paper provides a contemporary 
understanding of mainland Tanzania’s anti-malarial land-
scape. Overall, mainland Tanzania’s public sector is well 
prepared for malaria testing and treatment, with good 
levels of provider knowledge. The private sector how-
ever appears to have several gaps in its preparedness, 
which is reflective of reduced funding levels for the sub-
sidy programme since the AMFm. QA ACT availability 
and market share in the private sector continues to be 
disappointing for most outlet types, and there is persis-
tent widespread distribution of SP, which continues to 
predominate in the market. The reasons for this remain 
unclear, but are likely to be related to overall reduced 
funding of the ACT subsidy programme, such that afford-
able and more widely available SP remains in favourable 
competition to QA ACT. In the absence of supportive 
interventions, provider and consumer knowledge of the 
first-line treatment are also a barrier. Government drives 
for increased IPTp, while encouraging, are unlikely to 
fully explain the high levels of SP distribution. Continued 
efforts to implement government policy around malaria 
diagnosis and case management should be encouraged.
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